Patents by Inventor Fardos N. M. Naguib

Fardos N. M. Naguib has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of toxoplasmosis
    Patent number: 5773424
    Abstract: Pharmaceutical compositions comprising a pharmaceutical composition comprising a compound which is an .alpha. or .beta. anomer, a D(+) or L(-) enantiomer of the following structural formula: ##STR1## wherein, R.sub.1 is a halogen, OR.sub.6, SR.sub.6, SeR.sub.6 or CH.sub.2 R.sub.6 and R.sub.6 is alkyl, alkene, arylalkyl, or aryl; ##STR2## X is CH.sub.2, O or S; R.sub.3 is H, OH, or a halogen;R.sub.4 is H, OH, or a halogen; andR.sub.5 is CH.sub.3, CF.sub.3, CH.sub.2 OH, or CH.sub.2 OY and Y is a carbon ester or phosphorus; anda pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 16, 1994
    Date of Patent: June 30, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Mahmoud H. el Kouni, Vincent Guarcello, Fardos N. M. Naguib
  • Enzyme inhibitors, their synthesis, and methods for use
    Patent number: 5721241
    Abstract: Novel compounds are provided that are effective to inhibit the activity of DHUDase or UrdPase. Such compounds have the general formula ##STR1## where X is S or Se; Y H is I, F, Cl, Br, methoxy, benzyl, selenenylphenyl, or thiophenyl, and R.sub.1 is H or an acyclo tail having the general formula ##STR2## where R.sub.2 is H, CH.sub.2 OH or CH.sub.2 NH.sub.2 ; R.sub.3 is OH, NH.sub.2, or OCOCH.sub.2 CH.sub.2 CO.sub.2 H; and R.sub.4 is O, S, or CH.sub.2.The compounds can be used in pharmaceutical compositions, along with various chemotherapeutic agents to increase the efficacy of the treatment. These compounds can also be used in methods of treating patients by coadministering or sequentially administering the enzyme inhibiting compounds with a chemotherapeutic agent effective to treat cancers, or viral, fungal, bacterial, or parasitic infections. The compounds have further utility in enhancing imaging.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 24, 1998
    Assignees: Mahmoud H. el Kouni, Fardos N. M. Naguib, Raymond F. Schinazi
    Inventors: Mahmoud H. el Kouni, Fardos N. M. Naguib, Raymond F. Schinazi
  • Methods for optimizing fluoropyrimidine cancer therapy
    Patent number: 5670331
    Abstract: The present invention provides a method of predicting whether an individual will be intolerant to the effect of fluoropyrimidines comprising the step of measuring the activity of orotate phosphoribosyltransferase activity in a biological sample obtained from said individual. Also provided is a method of determining a non-toxic dose of 5-fluoruracil in an individual in need of fluoropyrimidine therapy, comprising the step of measuring the activity of 5-fluoruracil phosphoribosyltransferase (FUPRTase) in a biological sample obtained from said individual.
    Type: Grant
    Filed: June 22, 1995
    Date of Patent: September 23, 1997
    Assignee: The University of Alabama Research Foundation
    Inventors: Mahmoud H. el Kouni, Fardos N. M. Naguib
  • Enzyme inhibitors, their synthesis and methods for use
    Patent number: 5476855
    Abstract: Novel compounds are provided that are effective to inhibit the activity of DHUDase or UrdPase. Such compounds have the general formula ##STR1## where X is S or Se; Y is I, F, Cl, Br, methoxy, benzyl, selenenylphenyl, or thiophenyl, and R.sub.1 is an acyclo tail having the general formula ##STR2## where R.sub.2 is H, CH.sub.2 OH or CH.sub.2 NH.sub.2 ; R.sub.3 is OH, NH.sub.2, or OCOCH.sub.2 CH.sub.2 CO.sub.2 H; and R.sub.4 is O, S, or CH.sub.2.The compounds can be used in pharmaceutical compositions, along with various chemotherapeutic agents to increase the efficacy of the treatment. These compounds can also be used in methods of treating patients by coadministering or sequentially administering the enzyme inhibiting compounds with a chemotherapeutic agent effective to treat cancers, or viral, fungal, bacterial, or parasitic infections. The compounds have further utility in enhancing imaging.
    Type: Grant
    Filed: November 2, 1993
    Date of Patent: December 19, 1995
    Assignees: Mahmoud H. el Kouni, Fardos N. M. Naguib, F. Schinazi
    Inventors: Mahmoud el Kouni, Fardos N. M. Naguib, Raymond F. Schinazi
  • 5-benzyl barbiturate derivatives
    Patent number: 5141943
    Abstract: 5-benzyl barbiturate compounds for use as water-soluble uridine phosphorylase inhibitors are disclosed. These compounds are useful for reducing the toxicity and anemia induced by antiviral drugs such as AZT, as well as for potentiating anticancer drugs and combatting their host-toxicity.
    Type: Grant
    Filed: April 12, 1990
    Date of Patent: August 25, 1992
    Assignee: Brown University Research Foundation
    Inventors: Fardos N. M. Naguib, Mahmoud H. el Kouni, Raymond Panzica, Sungman Cha
  • Hydroxymethyl derivatives of 5-benzylacyclouridine and 5-benzoyloxybenzylacyclouridine and their use as potentiators for 5-fluoro-2'-deoxyuridine
    Patent number: 4613604
    Abstract: A compound of the Formula (I): ##STR1## where X is a benzyl group or a benzyloxybenzyl group and pharmaceutical preparations containing the same.
    Type: Grant
    Filed: July 31, 1985
    Date of Patent: September 23, 1986
    Assignee: Brown University Research Foundation
    Inventors: Shih H. Chu, Paul Calabresi, Ming Y. W. Chu, Mahmoud H. el Kouni, Fardos N. M. Naguib, Sungman Cha
  • Enzyme inhibitors, their synthesis, and methods for use
    Patent number: RE37623
    Abstract: Novel compounds are provided that are effective to inhibit the activity of DHUDase or UrdPase. Such compounds have the general formula where X is S or Se; Y is H, I, F, Cl, Br, methoxy, benzyl, selenenylphenyl, or thiophenyl, and R1 is H or an acyclo tail having the general formula where R2 is H, CH2 OH or CH2 NH2; R3 is OH, NH2, or OCOCH2CH2CO2H; and R4 is O, S, or CH2. The compounds can be used in pharmaceutical compositions, along with various chemotherapeutic agents to increase the efficacy of the treatment. These compounds can also be used in methods of treating patients by coadministering or sequentially administering the enzyme inhibiting compounds with a chemotherapeutic agent effective to treat cancers, or viral, fungal, bacterial, or parasitic infections. The compounds have further utility in enhancing imaging. Further, they can be administered alone to prevent and/or treat disorders of pyrimidine catabolism and other physiological disorders.
    Type: Grant
    Filed: December 1, 1997
    Date of Patent: April 2, 2002
    Inventors: Mahmoud H. el Kouni, Fardos N. M. Naguib, Raymond F. Schinazi